Cipla 미래 성장

Future 기준 확인 1/6

Cipla (는) 각각 연간 7.3% 및 8.2% 수익과 수익이 증가할 것으로 예상됩니다. EPS는 연간 7.4% 만큼 성장할 것으로 예상됩니다. 자기자본이익률은 3년 후 15% 로 예상됩니다.

주요 정보

7.3%

수익 성장률

7.4%

EPS 성장률

Pharmaceuticals 수익 성장	17.5%
매출 성장률	8.2%
향후 자기자본 수익률	15.0%
애널리스트 커버리지	Good
마지막 업데이트	17 Dec 2024

최근 미래 성장 업데이트

Cipla Limited Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year

Nov 01

Earnings Update: Cipla Limited (NSE:CIPLA) Just Reported Its Yearly Results And Analysts Are Updating Their Forecasts

May 14

Recent updates

We Ran A Stock Scan For Earnings Growth And Cipla (NSE:CIPLA) Passed With Ease

Dec 07

Cipla Limited Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year

Nov 01

Earnings Update: Cipla Limited (NSE:CIPLA) Just Reported Its Yearly Results And Analysts Are Updating Their Forecasts

May 14

With EPS Growth And More, Cipla (NSE:CIPLA) Makes An Interesting Case

May 03

Is Cipla (NSE:CIPLA) Using Too Much Debt?

Feb 14

Do Cipla's (NSE:CIPLA) Earnings Warrant Your Attention?

Jan 26

Getting In Cheap On Cipla Limited (NSE:CIPLA) Is Unlikely

Jan 08

수익 및 매출 성장 예측

NSEI:CIPLA - 애널리스트의 미래 추정치 및 과거 재무 데이터 (INR Millions )
날짜	수익	수익	잉여 현금 흐름	작전 현금	평균 애널리스트 수
3/31/2027	320,708	53,272	42,483	52,358	33
3/31/2026	300,630	52,162	40,673	51,001	37
3/31/2025	273,885	46,903	35,876	49,969	37
9/30/2024	262,642	44,751	29,520	45,008	N/A
6/30/2024	258,922	43,035	N/A	N/A	N/A
3/31/2024	255,367	41,216	27,846	41,339	N/A
12/31/2023	251,163	37,082	N/A	N/A	N/A
9/30/2023	243,407	34,532	25,988	37,924	N/A
6/30/2023	235,108	31,112	N/A	N/A	N/A
3/31/2023	225,593	28,019	20,736	32,377	N/A
12/31/2022	222,187	26,383	N/A	N/A	N/A
9/30/2022	218,874	25,660	20,120	29,160	N/A
6/30/2022	216,105	24,884	N/A	N/A	N/A
3/31/2022	217,078	25,168	26,285	33,259	N/A
12/31/2021	210,718	25,681	N/A	N/A	N/A
9/30/2021	207,616	25,876	28,362	37,113	N/A
6/30/2021	202,801	25,417	N/A	N/A	N/A
3/31/2021	191,205	24,049	29,418	37,552	N/A
12/31/2020	188,779	22,374	N/A	N/A	N/A
9/30/2020	180,802	18,403	23,627	31,968	N/A
6/30/2020	174,377	16,462	N/A	N/A	N/A
3/31/2020	170,805	15,465	20,684	30,685	N/A
12/31/2019	171,206	16,678	N/A	N/A	N/A
9/30/2019	167,572	16,489	18,294	25,720	N/A
6/30/2019	163,733	15,546	N/A	N/A	N/A
3/31/2019	163,232	15,277	11,640	16,911	N/A
12/31/2018	155,224	13,391	N/A	N/A	N/A
9/30/2018	154,287	14,074	N/A	N/A	N/A
6/30/2018	154,992	14,530	N/A	N/A	N/A
3/31/2018	151,053	14,105	N/A	14,628	N/A
12/31/2017	147,618	11,701	N/A	N/A	N/A
9/30/2017	144,951	11,444	N/A	N/A	N/A
6/30/2017	141,637	10,762	N/A	N/A	N/A
3/31/2017	143,340	10,064	N/A	23,818	N/A
12/31/2016	142,509	11,213	N/A	N/A	N/A
9/30/2016	137,547	10,071	N/A	N/A	N/A
6/30/2016	134,335	12,219	N/A	N/A	N/A
3/31/2016	135,480	13,600	N/A	17,408	N/A
12/31/2015	135,044	16,847	N/A	N/A	N/A
9/30/2015	131,633	16,694	N/A	N/A	N/A
6/30/2015	124,782	15,368	N/A	N/A	N/A
3/31/2015	113,454	11,808	N/A	11,734	N/A
12/31/2014	106,195	11,818	N/A	N/A	N/A
9/30/2014	105,627	11,383	N/A	N/A	N/A
6/30/2014	104,164	11,976	N/A	N/A	N/A
3/31/2014	101,734	13,884	N/A	15,633	N/A
12/31/2013	94,330	14,042	N/A	N/A	N/A

애널리스트 미래 성장 예측

수입 대 저축률: CIPLA 의 연간 예상 수익 증가율( 7.3% )이 saving rate( 6.7% 보다 높습니다. ).

수익 vs 시장: CIPLA 의 연간 수익( 7.3% ) Indian 시장( 18.1% 보다 느리게 성장할 것으로 예상됩니다. 18.1% 연간).

고성장 수익: CIPLA 의 수입은 증가할 것으로 예상되지만 상당히 증가하지는 않을 것입니다.

수익 대 시장: CIPLA 의 수익(연간 8.2% ) Indian 시장( 10.5% 보다 느리게 성장할 것으로 예상됩니다. 10.5% 연간).

고성장 수익: CIPLA 의 수익(연간 8.2% )은 연간 20% 보다 느리게 증가할 것으로 예상됩니다.

주당 순이익 성장 예측

미래 자기자본 수익률

미래 ROE: CIPLA 의 자본 수익률은 3년 내에 최저 수준이 될 것으로 예상됩니다( 15 %).

성장 기업 발견

기업 분석 및 재무 데이터 현황

데이터	마지막 업데이트(UTC 시간)
기업 분석	2024/12/24 12:22
장 마감 주가	2024/12/24 00:00
수익	2024/09/30
연간 수익	2024/03/31

데이터 소스

기업 분석에 사용된 데이터는 S&P Global Market Intelligence LLC의 데이터입니다. 이 보고서를 생성하기 위해 분석 모델에 사용된 데이터는 다음과 같습니다. 데이터는 정규화되어 있으므로 소스가 제공되기까지 지연이 발생할 수 있습니다.

패키지	데이터	기간	미국 소스 예시 ^*
회사 재무	10년	손익 계산서 현금 흐름표 대차 대조표	SEC 양식 10-K SEC 양식 10-Q
애널리스트 컨센서스 추정치	+3년	재무 예측 애널리스트 목표가	애널리스트 연구 보고서 Blue Matrix
시장 가격	30년	주식 가격 배당금, 분할 및 액션	ICE 시장 데이터 SEC 양식 S-1
소유권	10년	최대 주주 내부자 거래	SEC 양식 4 SEC 양식 13D
관리	10년	리더십 팀 이사회	SEC 양식 10-K SEC 양식 DEF 14A
주요 개발 사항	10년	회사 공지 사항	SEC 양식 8-K

* 미국 증권의 경우, 미국 외 지역의 규제 양식 및 출처가 사용된 예입니다.

명시되지 않는 한 모든 재무 데이터는 1년을 기준으로 하지만 분기별로 업데이트됩니다. 이를 후행 12개월(TTM) 또는 최근 12개월(LTM) 데이터라고 합니다. 여기에서 자세히 알아보세요.

분석 모델 및 눈송이

이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 Github 페이지에서 확인할 수 있으며, 보고서 사용 방법에 대한 가이드와 튜토리얼도 유튜브에서 확인할 수 있습니다.

Simply 월스트리트 분석 모델을 설계하고 구축한 세계적인 수준의 팀에 대해 알아보세요.

산업 및 부문 메트릭

업계 및 섹션 지표는 Simply Wall St에서 6시간마다 계산되며, 자세한 내용은 확인할 수 있습니다.

애널리스트 출처

Cipla Limited 74 애널리스트 중 37 애널리스트가 보고서의 입력 자료로 사용된 매출 또는 수익 추정치를 제출했습니다. 애널리스트의 제출 자료는 하루 종일 업데이트됩니다.

분석가	교육기관
Prashant Nair	Ambit Capital
Sriraam Rathi	Anand Rathi Shares and Stock Brokers Limited
null null	Anand Rathi Shares and Stock Brokers Limited

Cipla 미래 성장

Future 기준 확인 1/6

주요 정보

최근 미래 성장 업데이트

Cipla Limited Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year

Earnings Update: Cipla Limited (NSE:CIPLA) Just Reported Its Yearly Results And Analysts Are Updating Their Forecasts

Price target increased by 8.7% to ₹1,391

Price target increased to ₹1,208

Price target increased to ₹1,202

Consensus forecasts updated

Recent updates

We Ran A Stock Scan For Earnings Growth And Cipla (NSE:CIPLA) Passed With Ease

Cipla Promoters Reportedly May Sell 1.72% Stake Worth INR 20,000 Million via Block Deal

Cipla Limited Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year

Second quarter 2025 earnings: EPS exceeds analyst expectations

Cipla, Alkem Laboratories Reportedly in Final Lap to Buy SMT

Cipla Limited Announces Executive Appointments

Cipla Limited to Report Q2, 2025 Results on Oct 29, 2024

Cipla Limited's (NSE:CIPLA) Share Price Could Signal Some Risk

Cipla Limited Announces Resignation of M K Hamied as Vice Chairman and Non-Executive Director, Effective October 29, 2024

Cipla Limited Announces Retirement of S. Radhakrishnan, Non-Executive Director

Cipla Limited to Report Q1, 2025 Results on Jul 26, 2024

Cipla (NSE:CIPLA) Is Increasing Its Dividend To ₹13.00

Exelixis Announces Settlement of CABOMETYX® (cabozantinib) Patent Litigation with Cipla Limited and Cipla USA

Cipla's (NSE:CIPLA) Upcoming Dividend Will Be Larger Than Last Year's

Cipla Limited Approves the Appointment of Dr. Balram Bhargava as an Independent Director

Promoter Group Entities Reportedly Likely to Sell 2.5% Stake in Cipla worth INR 26.37 Billion via Block Deals

Earnings Update: Cipla Limited (NSE:CIPLA) Just Reported Its Yearly Results And Analysts Are Updating Their Forecasts

Dividend increased to ₹13.00

Cipla Limited, Annual General Meeting, Aug 20, 2024

Full year 2024 earnings: Revenues and EPS in line with analyst expectations

Cipla Limited Announces Retirement of S. Radhakrishnan as Non-Executive Director

With EPS Growth And More, Cipla (NSE:CIPLA) Makes An Interesting Case

Cipla Limited to Report Q4, 2024 Results on May 10, 2024

Cipla Limited Appoints Rajeev Kumar Sinha as Senior Management Personnel and Global Chief Manufacturing Officer, Effective April 1, 2024

Cipla Limited Appoints Venkata Sai Mungara as Senior Management Personnel and Global Head - Supply Chain, Effective from 1 April 2024

Is Cipla (NSE:CIPLA) Using Too Much Debt?

Price target increased by 8.7% to ₹1,391

Do Cipla's (NSE:CIPLA) Earnings Warrant Your Attention?

Cipla Limited Announces Resignation of Ms. Samina Hamied as Executive Vice Chairperson

Third quarter 2024 earnings: EPS exceeds analyst expectations

Getting In Cheap On Cipla Limited (NSE:CIPLA) Is Unlikely

Second quarter 2024 earnings released: EPS: ₹14.01 (vs ₹9.78 in 2Q 2023)

Torrent Pharmaceuticals Reportedly Bid to Acquire the Stake of Cipla Stalled over Valuation Differences

Torrent Pharma Calls the Reports of Cipla Acquisition as Speculative

Family Rift Clouds $7 Billion Sale of Cipla

Cipla Limited to Report Q2, 2024 Results on Oct 27, 2023

Blackstone Reportedly Withdraws Plan to Acquire Founders' Stake in Cipla

Torrent Pharma Reportedly in Advance Talks with CVC Capital to Buyout Cipla Promoters

Cipla's Founding Family's Stake Sale Reportedly in Jeopardy over $13 Billion Valuation Target

Bain Capital Reportedly Approaches Dr. Reddy's Laboratories to Explore Joint Bid to Buy Out the Promoters of Cipla

Torrent Pharmaceutical Leads in the Race to Acquire Cipla

Torrent Reportedly in Top Gear to Close Out Cipla Buyout, in Talks with PES, Banks for Funds

Torrent Reportedly Joins Fray for Hamied Family Stake in Cipla

Blackstone Reportedly to Submit Bid for over 33% Stake in Cipla

Cipla Promoters Reportedly Mull Stake Sale to Top PE Firms Blackstone, Baring Asia

Cipla Limited Announces Change in Management

Full year 2023 earnings: EPS misses analyst expectations

Cipla Limited, Annual General Meeting, Aug 10, 2023

Cipla Limited to Report Q1, 2024 Results on Jul 26, 2023

Shibam Group Holding Limited entered into a binding term sheet to acquire additional 51% stake in Saba Investment Ltd from Cipla Limited (NSEI:CIPLA) for $6.5 million.

Full year 2023 earnings: EPS misses analyst expectations

Cipla Limited Announces Resignation of Peter Mugyenyi as Independent Director, Effective May 13, 2023

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

Cipla Limited Announces the Launch of Cippoint

Cipla Limited to Report Q3, 2023 Results on Jan 25, 2023

Cipla Limited and Cipla Usa Inc. Announces the Launch of Leuprolide Acetate Injection Depot 22.5Mg

Price target increased to ₹1,208

Price target increased to ₹1,202

Second quarter 2023 earnings: EPS exceeds analyst expectations

Cipla Limited to Report Q2, 2023 Results on Nov 04, 2022

Cipla Limited Receives the Establishment Inspection Report Indicating Closure of the Inspection

Cipla Limited Declares Final Dividend for the Financial Year Ended March 31, 2022

Cipla Limited (NSEI:CIPLA) agreed to acquire additional 13.10% stake in Jiangsu Acebright Pharmaceutical Co. Limited for USD 16.40 million.

Cipla Limited Announces Executive Changes

Upcoming dividend of ₹5.00 per share

First quarter 2023 earnings released: EPS: ₹8.51 (vs ₹8.86 in 1Q 2022)

Cipla Limited, Annual General Meeting, Aug 26, 2022

Cipla Limited Recommends Final Dividend for Fiscal Year 2021-22

Cipla Limited to Report Q1, 2023 Results on Jul 29, 2022